Empowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
List view / Grid view
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
Scientists have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 laboratories, which makes it more efficient to study the virus, and to identify new treatments.
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
The Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access will offer researchers access to over 30 NMR spectrometers.
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.